0.425
-0.03 (-7.49%)
Previous Close | 0.459 |
Open | 0.439 |
Volume | 997,555 |
Avg. Volume (3M) | 12,400,730 |
Market Cap | 4,425,567 |
Price / Earnings (TTM) | 0.079 |
Price / Sales | 0.990 |
Price / Book | 0.780 |
52 Weeks Range |
Operating Margin (TTM) | -1,135.71% |
Diluted EPS (TTM) | 91.29 |
Quarterly Revenue Growth (YOY) | -55.30% |
Current Ratio (MRQ) | 5.65 |
Operating Cash Flow (TTM) | -6.13 M |
Levered Free Cash Flow (TTM) | -3.58 M |
Return on Assets (TTM) | -76.46% |
Return on Equity (TTM) | -149.34% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Mixed |
Medical Devices (Global) | Mixed | Mixed | |
Stock | Tivic Health Systems, Inc. | - | - |
AIStockmoo Score
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | 0.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -0.5 |
Average | 0.00 |
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body’s own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Value |
% Held by Insiders | 0.13% |
% Held by Institutions | 2.57% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
06 Mar 2025 | Announcement | Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System |
05 Mar 2025 | Announcement | Tivic Health Systems, Inc. Announces Reverse Stock Split |
03 Mar 2025 | Announcement | Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve |
24 Feb 2025 | Announcement | Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team |
12 Feb 2025 | Announcement | Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma |
23 Dec 2024 | Announcement | CEO Letter to Shareholders Issued by Tivic Health |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |